ODAC votes against use of PD-1 mAbs for PD-L1 low gastric, esophageal cancers

Part 2 of an interview with AstraZeneca’s head of oncology

A Q&A with EVP of oncology R&D, Susan Galbraith: Part 1

Global biotech sees Brukinsa and pipeline as growth engines as it relies on ‘CRO-free’ R&D model, protects supply chain

Overall survival may be losing its status as the key efficacy outcome of confirmatory cancer trials, but FDA takes OS seriously as safety

Plus: Pfizer’s, Genmab’s Tivdak gets priority review for full approval and more from Astellas, Cumulus, Pfizer and Innovent